Zura Bio (NASDAQ:ZURA) Earns Overweight Rating from Cantor Fitzgerald

Zura Bio (NASDAQ:ZURA)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports.

A number of other research analysts have also recently issued reports on ZURA. Piper Sandler reiterated an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Chardan Capital lowered their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Leerink Partners started coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target for the company. Finally, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a report on Monday, November 18th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Zura Bio Stock Down 12.4 %

NASDAQ:ZURA opened at $2.20 on Wednesday. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The business has a 50 day moving average price of $3.80 and a two-hundred day moving average price of $3.82.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, research analysts expect that Zura Bio will post -0.65 EPS for the current year.

Insider Activity

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 22.10% of the company’s stock.

Institutional Trading of Zura Bio

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares in the last quarter. Great Point Partners LLC raised its holdings in Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Armistice Capital LLC raised its holdings in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in Zura Bio in the second quarter worth about $43,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.